质子抑制剂的多颗粒系统的配方和表征,用于性的联合疗法
Prince Nikhil Rathore1, Alpana Ram1
1Department of Pharmacy, Guru Ghasidas Vishwavidyalaya, Bilaspur, C.G., 495009, India.
Recent advances in drug delivery and formulation
|July 15, 2025
概括
这项研究开发了持续释放的肠内涂层颗粒,结合了Amla提取物和埃索梅普拉,以有效治疗胃潰瘍. 这种新型配方在体外和体外模型中都表现出显著的抗活性.
科学领域:
- 制药科学 制药科学
- 药物输送系统 药物输送系统
- 胃肠病学 胃肠病学
背景情况:
- 胃潰瘍疾病需要有效的治療策略.
- 富含酸的阿姆拉提取物通过抑制胃H+/K+ ATPase,表现出抗的特性.
- 埃索梅普拉是一种质子抑制剂,通常用于与酸有关的疾病.
研究的目的:
- 为了开发持续释放的Amla提取物和埃索梅普拉的肠内涂层颗粒.
- 为了增强协同作用的抗效应,并减轻潜在的副作用.
- 为了实现药物释放时间延长和改善胃潰瘍治疗的治疗结果.
主要方法:
- 使用Soxhlet提取方法 (乙醇:水,7:3) 制备了Amla基提取物.
- 颗粒是使用湿颗粒制成的,并用基烯基甲基纤维素甲酸盐进行肠道涂层.
- 在试验室中,药物释放和捕获效率得到了优化;在活体中,在阿司匹林诱导的Wistar白色老鼠中评估了抗活性.
主要成果:
- 肠道涂层确保在pH 1.2 (模拟胃液) 时药物释放量微不足道,在pH 6.8 (模拟肠液) 时有效释放.
- 组合疗法在体内大鼠瘤模型中表现出显著的治疗疗效.
- 优化的颗粒显示了持续释放特性和有效的药物捕获.
结论:
- 持续释放的Amla提取物和埃索梅普拉的肠内涂层颗粒已经成功开发出来.
- 组合疗法在治疗胃潰瘍方面显示出显著的积极效果,得到了各种疗效参数的支持.
- 该配方通过协同作用和可控的药物递送提供了一种有前途的方法,用于通过协同作用和可控的药物递送来加强胃潰瘍的治疗.
相关概念视频
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
530
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
530
Peptic Ulcer Disease IV: Management
146
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
146
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
588
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
588
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
600
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
600
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
700
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
700
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
554
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
554


